[Can coronary risks be further reduced?].
Tedgu
A
A
INSERM U541, Hôpital Lariboisière, Paris, France.
Dagenais
G
G
Marre
M
M
Chierchia
S-L
SL
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000150:complications* / Q000209:etiology*; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D007249:Inflammation; D009203:Myocardial Infarction / Q000209:etiology; D011379:Prognosis; D017257:Ramipril / Q000627:therapeutic use; D012307:Risk Factors; D020521:Stroke / Q000209:etiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D002097:C-Reactive Protein; D017257:Ramipril